4/18/14. Background. Evaluation of a Morphine Weaning Protocol in Pediatric Intensive Care Patients. Background. Signs and Symptoms of Withdrawal
|
|
- Kory Perry
- 8 years ago
- Views:
Transcription
1 Background 1 Evaluation of a Morphine Weaning Protocol in Pediatric Intensive Care Patients Alyssa Cavanaugh, PharmD PGY1 Pharmacy Resident Children s Hospital of Michigan **The speaker has no actual or potential conflict of interest in relation to this presentation** 2 Long-term opioid infusions are needed for intensive care unit (ICU) patients to manage pain Sedation used to prevent Accidental self-extubation Catheter removal Reduce morbidity associated with inadequate management of distress Can J Hosp Pharm Vol 65(1):12-18 Background Signs and Symptoms of Withdrawal Withdrawal: Clinical syndrome that manifests after stopping or reversing a drug after prolonged exposure Primary Mechanism Opioid receptor coupling to Gs protein Superactivation of camp pathway Activation of excitatory amino acid receptors 3 Categories of Symptoms CNS irritability GI dysfunction Autonomic dysfunction Anxiety Agitation Tremors Seizures Vomiting Diarrhea Poor feeding Fever Sweating High blood pressure Yawning 3 Pediatrics Vol 125:e1208-e Can J Hosp Pharm Vol 65(1):12-18 Learning Question #1 Which of the following are signs and symptoms of opioid withdrawal? A. Tremor B. High blood pressure C. Vomiting D. All of the above Withdrawal Assessment Withdrawal is a common side effect of prolonged sedation in a pediatric intensive care unit (PICU) Method of assessment and monitoring is warranted Withdrawal Assessment Tool-1 (WAT-1): evaluates withdrawal symptoms in a PICU setting 5 6 Pediatr Crit Care Med Vol 9(6):
2 Withdrawal Assessment Withdrawal Assessment Tool-1 Validity and generalizability of the Withdrawal Assessment Tool-1 (WAT-1) for monitoring iatrogenic withdrawal syndrome in pediatric patients Purpose Conclusion To investigate the validity and generalizability of the Withdrawal Assessment Tool-1 (WAT-1) in children during weaning of analgesics and sedatives All subjects exposed to 5 or more consecutive days of opioids had been assessed for withdrawal symptoms twice daily at 8 am and 8 pm (and at other times if clinically indicated) from the day that opioid weaning started until 72 hours after last opioid dose 308 children throughout 22 centers Higher WAT-1 scores (> 3) had a longer PICU length of stay than those with WAT-1 scores (<3) WAT-1 demonstrated feasibility and utility as evidenced by its successful implementation and use by nurses in major pediatric centers across the USA WAT-1 shows good generalizability when used to assess clinically important withdrawal symptoms in the PICU 7 Pain 2012 January. Vol 153(1): Pain 2012 January. Vol 153(1): Opioid Pharmacokinetics Half-life Learning Question #2 What is the half-life of oral morphine? A hours B hours C hours D. All of the above 9 Am J Dis Child August. Vol 146: Previous Studies Study Rationale Children s Hospital of Michigan Historical Controls (unpublished data) January 1st, 2010 to September 30th, 2012 October 1st, 2012 to March 1st, Methadone wean Retrospective n=64 Average wean: days (1-111) Average rescue doses: 42 doses/wean (0-695) Average cost/wean: $4.52 ( ) Longer weans Multiple rescue doses needed during wean Morphine 2-arm wean (10 day and 20 day) Prospective n=24 Average wean: 8.75 days (2-19) Average rescue doses: 3.3 doses/wean (0-15) Average cost/wean: $3.15 ( ) Patients finished wean faster than allotted time WAT-1 scores were not accurately recorded or lack of recordings 12 2
3 Purpose Evaluation of a Morphine Weaning Protocol in Pediatric Intensive Care Patients Describe the incidence of opioid withdrawal in pediatric patients using a 3-arm morphine weaning protocol Primary investigator: Alyssa Cavanaugh, PharmD Secondary investigators: Joanna Ditouras, PharmD, Kevin Valentine, MD Children s Hospital of Michigan Detroit Medical Center Study Outcomes Primary Outcome Incidence of opioid withdrawal in pediatric patients Secondary Outcomes Identify adherence to protocol Compare the duration of medication therapy and cost Compare the length of ICU stay All patients were placed in a wean protocol if they had been on continuous infusion morphine for > 5 days # of Infusion Days Wean 5-10 days 5 day Patients were divided into 3 different groups 5 day wean 10 day wean 15 day wean days 10 day > 16 days 15 day
4 Calculate the Original Daily Dose (ODD) Morphine Oral (mg) ODD= 2X (Total of IV bolus + infusion from previous day) Example: 10 kg pt Infusion: 40 mcg/kg/hr Bolus: 0.4 mg IV q2hr = 6 bolus/24hrs Day 5 DAY MORPHINE WEAN Original Daily Dose (ODD)= 2X(Total of IV bolus+infusion from previous day) 1 Divide ODD every 6 hours 2 Decrease to 80% of ODD and divide every 6 hours 3 Decrease to 60% of ODD and divide every 8 hours 4 Decrease to 40% of ODD and divide every 12 hours 5 Decrease to 20% of ODD and divide every 12 hours 6 Discontinue morphine 23 Day 10 DAY MORPHINE WEAN Original Daily Dose (ODD)= 2X(Total of IV bolus+infusion from previous day) 1 Divide ODD every 4 hours 2 Decrease to 90% of ODD and divide every 4 hours 3 Decrease to 80% of ODD and divide every 6 hours 4 Decrease to 70% of ODD and divide every 6 hours 5 Decrease to 60% of ODD and divide every 8 hours 6 Decrease to 50% of ODD and divide every 8 hours 7 Decrease to 40% of ODD and divide every 12 hours 8 Decrease to 30% of ODD and divide every 12 hours 9 Decrease to 20% of ODD and give every 12 hours 10 Decrease to 10% of ODD and give every 12 hours 11 Discontinue morphine 15 DAY MORPHINE WEAN Day Original Daily Dose (ODD)= 2X(Total of IV bolus+infusion from previous day) 1 Divide ODD every 4 hours WAT-1 scoring from the 1st day of wean 2 Decrease to 90% of ODD and divide every 4 hours 3 no change 4 Decrease to 80% of ODD and divide every 6 hours 5 Decrease to 70% of ODD and divide every 6 hours Scored twice daily (once per nursing shift) 6 no change 7 Decrease to 60% of ODD and divide every 8 hours 8 Decrease to 50% of ODD and divide every 8 hours Continued until 72 hours after the last dose 9 no change 10 Decrease to 40% of ODD and divide every 12 hours 11 Decrease to 30% of ODD and divide every 12 hours 12 no change 13 Decrease to 20% of ODD and divide every 12 hours 14 Decrease to 10% of ODD and divide every 12 hours 15 no change Discontinue morphine 25 4
5 Rescue Dose If patients received 3 or more doses for breakthrough in a 24 hour period with appropriate WAT-1 score confirmation, then patients were moved back by 2 days Example: A child on day 3 of a wean received 3 breakthrough (not counting for pain or procedures) doses of morphine with confirming WAT-1 scores, then go back to day 1 of protocol Statistical Analysis Descriptive statistics were used to: Evaluate demographic and visit characteristics Identify incidence of withdrawal Identify adherence to protocol Describe the duration of therapy, cost, and length of ICU stay Background Demographics Primary Outcome: Incidence of opioid withdrawal in pediatric patients WAT-1 scores # of rescue doses/wean Adherence to Protocol 30 WAT-1 Scores 100% had at least one WAT-1 78% had a daily WAT-1 56% had a twice daily WAT-1 Rescue Doses 14 total doses (0.52 doses/wean) 9/14 had a documented WAT-1 > 3 and gave rescue dose 4/14 described signs and symptoms of withdrawal and gave rescue dose 1/14 had rescue dose given with no signs and symptoms or WAT-1 score 31 5
6 Confounders Secondary outcomes Duration of medication therapy Continuous infusion Average = 10.2 days (4-40) Taper Average = 9.52 days (4-25) Cost of therapy Average = $7.97/wean ( ) Length of ICU stay Average = 32.3 days (9-148) Length of hospital stay Average = 36.1 days (12-148) Discussions Morphine comparisons Outcomes Length of continuous infusion Duration of medication therapy (Historical Controls) October 1st, 2012 to March 1st, 2013 (Current Data) October 1st, 2013 to March 1st, days (5-23) 10.2 days (4-40) 8.75 days (2-19) 9.52 days (4-25) # of morphine doses doses (4-78) doses (8-73) Cost of therapy $3.15 ( ) $7.97 ( ) Length of ICU stay 21 days (8-44) 32.3 days (9-148) Conclusions 67% adherence to protocol Cardiovascular patients had longer weans than those admitted for a respiratory diagnosis Better compliance for completion of WAT-1 scores by PICU staff 93% rescue doses given were addressed either through WAT-1 score or described signs and symptoms Conclusions Limitations Compared to 2-arm wean Small study, n = 27 Single center Excluded patients on high dose opioid infusions WAT-1 is a subjective scale assessed by multiple RNs in PICU and floor Patients transferred to floor Patients discharged prior to wean finishing
7 Future Directions WAT-1 scores to be incorporated on flow sheets for PICU and EMR for floor patients Formal teaching will be expanded beyond PICU to floor teams and nurses Evaluate if a cardiovascular specific wean needs to be created Evaluate if high WAT-1 scores on day 1 require an increased ODD or a move up to next wean category Acknowledgements Dr. Joanna Ditouras, PharmD and Dr. Kevin Valentine, MD Children s Hospital of Michigan PICU staff Selmir Mahmutovic, PharmD Candidate 2015 and Matthew Duprey, PharmD Candidate Evaluation of a Morphine Weaning Protocol in Pediatric Intensive Care Patients 40 Alyssa Cavanaugh, PharmD Children s Hospital of Michigan Detroit Medical Center 7
Evaluation of a Morphine Weaning Protocol in Pediatric Intensive Care Patients
Evaluation of a Morphine Weaning Protocol in Pediatric Intensive Care Patients Jennifer Kuhns, Pharm.D. Pharmacy Practice Resident Children s Hospital of Michigan **The speaker has no actual or potential
More informationWITHDRAWAL OF ANALGESIA AND SEDATION
WITHDRAWAL OF ANALGESIA AND SEDATION Patients receiving analgesia and/or sedation for longer than 5-7 days may suffer withdrawal if these drugs are suddenly stopped. To prevent this happening drug doses
More informationManagement of Neonatal Abstinence Syndrome and Iatrogenic Drug Withdrawal
Management of Neonatal Abstinence Syndrome and Iatrogenic Drug Withdrawal Kirsten H. Ohler, Pharm.D., BCPS Clinical Assistant Professor Neonatal / Pediatric Clinical Pharmacist University of Illinois at
More informationMethadone dosage for prevention of opioid withdrawal in children
Paediatric Anaesthesia 2003 13: 805 810 Methadone dosage for prevention of opioid withdrawal in children RAJASHEKHAR SIDDAPPA MD*, JAMES E. FLETCHER MBBS, ANDREW M.B. HEARD MBChB, DONNA KIELMA RN, MICHAEL
More informationNEONATAL ABSTINENCE SYNDROME AND SCORING SYSTEM
VIDANT MEDICAL CENTER PATIENT CARE _ SUBJECT: Abstinence Scoring NUMBER: A-1 PAGE: 1 OF: 5 _ NEONATAL ABSTINENCE SYNDROME AND SCORING SYSTEM POLICY: A thorough evaluation of the infant is required in order
More informationAssessment and Management of Opioid, Benzodiazepine, and Sedative-Hypnotic Withdrawal
Assessment and Management of Opioid, Benzodiazepine, and Sedative-Hypnotic Withdrawal Roger Cicala, M. D. Assistant Medical Director Tennessee Physician s Wellness Program Step 1 Don t 1 It is legal in
More informationPrevention and Treatment of Opioid and Benzodiazepine Withdrawal
1.0 Introduction The purpose of this guideline is to ensure that patients who are at risk of developing withdrawal symptoms can be weaned off opioids and benzodiazepines in a timely fashion. It is appropriate
More informationNew York State Office of Alcoholism & Substance Abuse Services Addiction Services for Prevention, Treatment, Recovery
New York State Office of Alcoholism & Substance Abuse Services Addiction Services for Prevention, Treatment, Recovery USING THE 48 HOUR OBSERVATION BED USING THE 48 HOUR OBSERVATION BED Detoxification
More informationWhat is Methadone? Opioid Treatment Programs Today. Is Methadone Safe? Pain Clinics. Wisconsin OTPs. Methadone Maintenance Treatment 5/6/2013
Methadone Maintenance Treatment Tanya Hiser, MS, LPC State Opioid Treatment Authority April 22, 2013 What is Methadone? Schedule II pharmaceutical opioid similar to Oxycodone or morphine. Binds to the
More informationSymptom Based Alcohol Withdrawal Treatment
Symptom Based Alcohol Withdrawal Treatment -Small Rural Hospital- Presenter CDR Dwight Humpherys, DO dwight.humpherys@ihs.gov Idaho State University Baccalaureate Nursing Program Lake Erie College of Osteopathic
More informationNEONATAL ABSTINENCE SYNDROME. Osama Naga, M.D. PGY2
NEONATAL ABSTINENCE SYNDROME Osama Naga, M.D. PGY2 Objective: Describe the common causes of NAS Clinical Presentation Diagnosis Identify the different scoring system for pharmacologic therapy Minimize
More informationIdentifying Neonatal Abstinence Syndrome (NAS) and Treatment Guidelines University of Iowa Children s Hospital -2/11/13
Identifying Neonatal Abstinence Syndrome (NAS) and Treatment Guidelines University of Iowa Children s Hospital -// What is Neonatal Abstinence Syndrome? Neonatal withdrawal after intrauterine exposure
More informationTreatment Guidelines for Neonatal Narcotic Abstinence Syndrome with Diluted Oral Morphine and Clonidine
Treatment Guidelines for Neonatal Narcotic Abstinence Syndrome with Diluted Oral Morphine and Clonidine Background Morphine sulfate has been recommended by the AAP as the first-line agent for the pharmacologic
More informationReview of Pharmacological Pain Management
Review of Pharmacological Pain Management CHAMP Activities are possible with generous support from The Atlantic Philanthropies and The John A. Hartford Foundation The WHO Pain Ladder The World Health Organization
More informationSubstance Use Guideline 4B PERINATAL OPIOID EXPOSURE, CARE OF THE NEWBORN
British Columbia Reproductive Care Program Substance Use Guideline 4B PERINATAL OPIOID EXPOSURE, CARE OF THE NEWBORN INTRODUCTION During the antenatal period, the opportunity exists for the primary care
More informationPhenobarbital in Severe Alcohol Withdrawal Syndrome. Jordan Rowe Pharm.D. Candidate UAMS College of Pharmacy
Phenobarbital in Severe Alcohol Withdrawal Syndrome Jordan Rowe Pharm.D. Candidate UAMS College of Pharmacy Disclosure: No relevant financial relationship exists. Objectives 1. Describe the pathophysiology
More informationWithdrawal symptoms in long term sedation exposure of pediatric intensive care patients
CLINICAL PRACTICE Withdrawal symptoms in long term sedation exposure of pediatric intensive care patients Susanne Kotz University Medical Center Hamburg-Eppendorf, Germany Correspondence: Susanne Kotz.
More informationPain Management in the Critically ill Patient
Pain Management in the Critically ill Patient Jim Ducharme MD CM, FRCP President-Elect, IFEM Clinical Professor of Medicine, McMaster University Adjunct Professor of Family Medicine, Queens University
More informationPOST-TEST Pain Resource Professional Training Program University of Wisconsin Hospital & Clinics
POST-TEST University of Wisconsin Hospital & Clinics True/False/Don't Know - Circle the correct answer T F D 1. Changes in vital signs are reliable indicators of pain severity. T F D 2. Because of an underdeveloped
More informationIntroduction to Neonatal Abstinence Syndrome
Introduction to Neonatal Abstinence Syndrome Cara Christ, MD Director, Arizona Department of Health Services Learning Objectives 1.Define Neonatal Abstinence Syndrome 2.Describe Neonatal Abstinence Syndrome
More informationSaint Thomas Hospital Protocol. Protocol Title: Terminal Weaning from Ventilator Protocol No.: V-09. Medical Staff departments
Saint Thomas Hospital Protocol Protocol No.: V-09 Operating Unit(s) Medical Staff departments Important s: Affected: affected:! Hospital! Medicine of Origin: 2/00 " Regional Network! Surgery Reviewed:
More informationWeaning off your pain medicine
Weaning off your pain medicine UHN Information for patients taking opioid pain medicines Read this booklet to learn about: why you need to wean off your pain medicine how to wean off slowly how to control
More informationPain Medication Taper Regimen Time frame to taper off 30-60 days
Pain Medication Taper Regimen Time frame to taper off 30-60 days Medication to taper Taper Regimen Comments Methadone Taper by no more than 25% Morphine Taper by no more than 25% Tramadol Taper by no more
More informationNurses Self Paced Learning Module on Pain Management
Nurses Self Paced Learning Module on Pain Management Dominican Santa Cruz Hospital Santa Cruz, California Developed by: Strategic Planning Committee Dominican Santa Cruz Hospital 1555 Soquel Drive Santa
More informationAppendix to Tennessee Department of Health: Tennessee Clinical Practice Guidelines for Outpatient Management of Chronic Non- Malignant Pain
Appendix to Tennessee Department of Health: Tennessee Clinical Practice Guidelines for Outpatient Management of Chronic Non- Malignant Pain Division of Workers Compensation 04.01.2015 Background Opioids
More informationWithdrawal Symptoms: How Long Do They Last?
Withdrawal Symptoms: How Long Do They Last? Posted by First Step Medical Detox on November 24, 2015 When considering stopping drugs or alcohol, many addicts and alcoholics are concerned about the withdrawal
More information1. According to recent US national estimates, which of the following substances is associated
1 Chapter 36. Substance-Related, Self-Assessment Questions 1. According to recent US national estimates, which of the following substances is associated with the highest incidence of new drug initiates
More informationAlcohol Withdrawal. Introduction. Blood Alcohol Concentration. DSM-IV Criteria/Alcohol Abuse. Pharmacologic Effects of Alcohol
Pharmacologic Effects of Alcohol Alcohol Withdrawal Kristi Theobald, Pharm.D., BCPS Therapeutics III Fall 2003 Inhibits glutamate receptor function (NMDA receptor) Inhibits excitatory neurotransmission
More informationCONTROLLED SUBSTANCE CONTRACT
CONTROLLED SUBSTANCE CONTRACT The purpose of this contract is to protect my access to controlled substances and to protect our ability to prescribe for you. The long-term use of substances such as opiates
More informationSutter Health: Sacramento-Sierra REGIONAL ICU DELIRIUM PROTOCOL
Sutter Health: Sacramento-Sierra REGIONAL ICU DELIRIUM PROTOCOL Delirium-(acute brain dysfunction) is defined as a disturbance of consciousness with inattention accompanied by a change in cognition or
More informationBenzodiazepines: A Model for Central Nervous System (CNS) Depressants
Benzodiazepines: A Model for Central Nervous System (CNS) Depressants Objectives Summarize the basic mechanism by which benzodiazepines work in the brain. Describe two strategies for reducing and/or eliminating
More informationAbstral Prescriber and Pharmacist Guide
Abstral Prescriber and Pharmacist Guide fentanyl citrate sublingual tablets Introduction The Abstral Prescriber and Pharmacist Guide is designed to support healthcare professionals in the diagnosis of
More information(peak at 2 days 6 wks)
Perinatal Manual of Southwestern Ontario A collaboration between the Regional Perinatal Outreach Program of Southwestern Ontario & the Southwestern Ontario Perinatal Partnership (SWOPP) Chapter 46 NEONATAL
More informationPROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain
P a g e 1 PROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain Clinical Phase 4 Study Centers Study Period 25 U.S. sites identified and reviewed by the Steering Committee and Contract
More informationAcute Pain Management in the Opioid Dependent Patient. Maripat Welz-Bosna MSN, CRNP-BC
Acute Pain Management in the Opioid Dependent Patient Maripat Welz-Bosna MSN, CRNP-BC Relieving Pain in America (IOM) More then 116 Million Americans have pain the persists for weeks to years $560-635
More informationEmergency and inpatient treatment of migraine: An American Headache Society
Emergency and inpatient treatment of migraine: An American Headache Society survey. The objective of this study was to determine the practice preferences of AHS members for acute migraine treatment in
More informationGuidance for Disease Management in Correctional Settings OPIOID DETOXIFICATION
1145 W. Diversey Pkwy. 773-880-1460 Chicago, Illinois 60614 www.ncchc.org Guidance for Disease Management in Correctional Settings OPIOID DETOXIFICATION NCCHC issues guidance to assist correctional health
More informationCase. History of psoriatic arthritis, htn, essential tremor Meds: propranolol, etodolac, etanercept No history of prior psychiatric disease.
Case 48 year old man admitted complaining of hallucinations. Mild hallucinations for a year. Worsened tremor for 3 weeks and then markedly worse hallucinations last 2 days History of psoriatic arthritis,
More informationInhibit terminal acid secretion from parietal cells by blocking H + /K + - ATPase pump
Chris J. Taylor, Pharm.D., BCPS Clinical Pharmacist Phoenix VA Health Care System Review pharmacology of PPIs Discuss possible association between PPI use and development of the following: Pneumonia (community-acquired
More informationCOMMUNITY BUPRENORPHINE PRESCRIBING IN OPIATE DEPENDENCE
COMMUNITY BUPRENORPHINE PRESCRIBING IN OPIATE DEPENDENCE INTRODUCTION High dose sublingual buprenorphine (Subutex) tablets are available in the following strengths 0.4 mg, 2 mg, and 8 mg. Suboxone tablets,
More informationAlcohol Withdrawal Syndromes
Alcohol Withdrawal Syndromes Should You Treat This Patient s Alcohol Withdrawal With Benzodiazepines?! Meta-analysis of RCTs of benzodiazepines for the treatment of alcohol withdrawal! 11 RCTs identified,
More informationUniversity of Michigan Alcohol Withdrawal Guidelines Overview
University of Michigan Alcohol Withdrawal Guidelines Overview The following document contains the University of Michigan Alcohol Withdrawal Guidelines. These guidelines were developed through an intensive
More informationCHILDREN S SERVICES. Neonatal Abstinence Syndrome
CHILDREN S SERVICES Neonatal Abstinence Syndrome Background Neonatal Abstinence Syndrome (NAS) is a combination of behavioural and physiological signs and symptoms that occur in newborns going through
More information9/16/2010. Contact Information. Objectives. Analgesic Ketamine (Ketalar )
Analgesic Ketamine (Ketalar )..the long and winding road to clinical practice Contact Information Lois Pizzi BSN, RN-BC Inpatient Pain Management Clinician UPMC Presbyterian Shadyside pizzilj@upmc.edu
More informationNaloxone treatment of opioid overdose
Naloxone treatment of opioid overdose Opioids Chemicals that act in the brain to relieve pain, often use to suppress cough, treat addiction, and provide comfort After prolonged use of opioids, increasing
More informationNaltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance
Naltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance Introduction Indication/Licensing information: Naltrexone is licensed for use as an additional therapy, within
More informationHow To Treat An Alcoholic Patient
Height Weight Allergies If appropriate for patient condition, please consider the following order sets: Initiate Electrolyte Replcement: Med/Surg, Med/Surg Tele Physician Order #842 Discontinue all lorazepam
More informationTreatment of Opioid Dependence with Buprenorphine/Naloxone (Suboxone )
Treatment of Opioid Dependence with Buprenorphine/Naloxone (Suboxone ) Elinore F. McCance-Katz, M.D., Ph.D. Professor and Chair, Addiction Psychiatry Virginia Commonwealth University Neurobiology of Opiate
More informationOpiate Treatment for Aboriginal High School Students in Ontario
Opiate Treatment for Aboriginal High School Students in Ontario January 2014 1 CHALLENGE About 40% of the students at an Aboriginal high school in Thunder Bay Ontario (Canada) are known to be addicted
More informationHow To Know If You Should Be Treated
Comprehensive ehavioral Care, Inc. delivery system that does not include sufficient alternatives to a particular LOC and a particular patient. Therefore, CompCare considers at least the following factors
More informationNALTREXONE INDUCED DETOXIFICATION FROM OPIOIDS A METHOD OF ANTAGONIST INITIATED TREATMENT
NALTREXONE INDUCED DETOXIFICATION FROM OPIOIDS A METHOD OF ANTAGONIST INITIATED TREATMENT Opioid dependence is a devastating and frequently fatal medical condition. It is a manifestation of addictive disorder
More informationAfter seeing a patient on a Diversion Alert installment..
After seeing a patient on a Diversion Alert installment.. Recommendations from Dr. James Berry of Mercy Recovery Center OVERVIEW OF DIVERSION Manufacture Distribution Pharmacy Patient End -user OPPORTUNITIES
More informationSELECTED OPIATES TOXICITY A MODERN DAY EPIDEMIC
SELECTED OPIATES TOXICITY A MODERN DAY EPIDEMIC Learning Objectives: 1. Identify the names and reasons/circumstances for additional toxicity of SELECTED OPIATES hydromorphone DILAUDID Methadone Fentanyl/DURAGESIC
More informationMODERATE SEDATION RECORD (formerly termed Conscious Sedation)
(POLICY #DOC-051) Page 1 of 6 WELLSPAN HEALTH - YORK HOSPITAL NURSING POLICY AND PROCEDURE Dates: Original Issue: September 1998 Annual Review: March 2012 Revised: March 2010 Submitted by: Brenda Artz
More informationMedical Malpractice Treatment Alprazolam benzodiazepine - A Case Study
Improving Outcomes in Patients Who are Prescribed Alprazolam with Concurrent Use of Opioids Pik-Sai Yung, M.D. Staff Psychiatrist Center for Counseling at Walton Background and Rationale Alprazolam is
More informationBlueprint for Prescriber Continuing Education Program
CDER Final 10/25/11 Blueprint for Prescriber Continuing Education Program I. Introduction: Why Prescriber Education is Important Health care professionals who prescribe extended-release (ER) and long-acting
More informationThe Pharmacological Management of Cancer Pain in Adults. Clinical Audit Tool
The Pharmacological Management of Cancer Pain in Adults Clinical Audit Tool 2015 This clinical audit tool accompanies the Pharmacological Management of Cancer Pain in Adults NCEC National Clinical Guideline
More informationSupported Alcohol Withdrawal Treatment Information
Supported Alcohol Withdrawal Treatment Information Alcohol Liaison Service What is Alcohol Withdrawal Syndrome? If you are dependent on alcohol and suddenly stop drinking or you are admitted to hospital
More informationRecommendations for Alternative Analgesic and Sedative Agents in the Setting of Drug Shortages
Recommendations for Alternative Analgesic and Sedative Agents in the Setting of Drug Shortages Gail Gesin, PharmD* Clinical Phramacist for Trauma Critical Care Carolinas Medical Center Charlotte, North
More informationGuidelines for Cancer Pain Management in Substance Misusers Dr Jane Neerkin, Dr Chi-Chi Cheung and Dr Caroline Stirling
Guidelines for Cancer Pain Management in Substance Misusers Dr Jane Neerkin, Dr Chi-Chi Cheung and Dr Caroline Stirling Patients with a substance misuse history are at increased risk of receiving inadequate
More informationMEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION
MEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION Mark Fisher Program Administrator State Opioid Treatment Adminstrator Kentucky Division of Behavioral Health OBJECTIVES Learn about types of opioids and
More informationMEDICATION GUIDE. What is Morphine Sulfate Oral Solution?
MEDICATION GUIDE Morphine Sulfate (mor-pheen) (CII) Oral Solution IMPORTANT: Keep Morphine Sulfate Oral Solution in a safe place away from children. Accidental use by a child is a medical emergency and
More informationOpioid Addiction and Methadone: Myths and Misconceptions. Nicole Nakatsu WRHA Practice Development Pharmacist
Opioid Addiction and Methadone: Myths and Misconceptions Nicole Nakatsu WRHA Practice Development Pharmacist Learning Objectives By the end of this presentation you should be able to: Understand how opioids
More informationDowners/Depressants (pages 40-50)
Downers/Depressants (pages 40-50) Read pages 49-54, 59-60, and 78-79 of the booklet, Street Drugs. Pages 40-50 of the text. Narcotics: Prescription Origin: Southeast Asia, Southwest Asia, and in the Western
More informationSubstitution Therapy for Opioid Dependence The Role of Suboxone. Mandy Manak, MD, ABAM, CCSAM Methadone 101-Hospitalist Workshop, October 3, 2015
Substitution Therapy for Opioid Dependence The Role of Suboxone Mandy Manak, MD, ABAM, CCSAM Methadone 101-Hospitalist Workshop, October 3, 2015 Objectives Recognize the options available in treating opioid
More informationGuidelines for the Use of Naloxone in Palliative Care in Adult Patients
Guidelines for the Use of Naloxone in Palliative Care in Adult Patients Date Approved by Network Governance May 2012 Date for Review May 2015 Changes between Version 1 and 2 1. Guideline background 2.
More informationPHYSICIAN SIGNATURE DATE TIME DRUG ALLERGIES WT: KG
DRUG AND TREATMENT Condition/Status This powerplan is only intended for use in those patients having symptoms related to alcohol withdrawal. See DSM-IV-TR criteria listed in the Alcohol Withdrawal ICU
More informationGuidelines for the Prescribing, Supply and Administration of Methadone and Buprenorphine on Transfer of Care
Hull & East Riding Prescribing Committee Guidelines for the Prescribing, Supply and Administration of Methadone and Buprenorphine on Transfer of Care 1. BACKGROUND Patients who are physically dependent
More informationManagement of Pregnancy. Opioid Addiction Treatment
Management of Pregnancy Opioid Addiction Treatment Perinatal Opioid Addiction Pharmacotherapy and co-ordination of care are essential elements in the comprehensive care of pregnant patients with opioid
More informationOmega-3 fatty acids improve the diagnosis-related clinical outcome. Critical Care Medicine April 2006;34(4):972-9
Omega-3 fatty acids improve the diagnosis-related clinical outcome 1 Critical Care Medicine April 2006;34(4):972-9 Volume 34(4), April 2006, pp 972-979 Heller, Axel R. MD, PhD; Rössler, Susann; Litz, Rainer
More informationNeonatal Abstinence Syndrome
Neonatal Abstinence Syndrome D COGHLAN, *M MILNER, T CLARKE, I LAMBERT, C MCDERMOT, M MCNALLY, M BECKETT. T MATTHEWS Department of Paediatrics and *Obstetrics. Rotunda Hospital. Parnell Square. Dublin
More informationOPIOIDS. Petros Levounis, MD, MA Chair Department of Psychiatry Rutgers New Jersey Medical School
OPIOIDS Petros Levounis, MD, MA Chair Department of Psychiatry Rutgers New Jersey Medical School Rutgers New Jersey Medical School Fundamentals of Addiction Medicine Summer Series Newark, NJ July 24, 2013
More informationPolicy for the issue of permits to prescribe Schedule 8 poisons
Policy for the issue of permits to prescribe Schedule 8 poisons May 2011 Introduction The Victorian Drugs, Poisons and Controlled Substances (DPCS) legislation sets out certain circumstances when a medical
More informationUNIT VIII NARCOTIC ANALGESIA
UNIT VIII NARCOTIC ANALGESIA Objective Review the definitions of Analgesic, Narcotic and Antagonistic. List characteristics of Opioid analgesics in terms of mechanism of action, indications for use and
More informationThe Federation of State Medical Boards 2013 Model Guidelines for Opioid Addiction Treatment in the Medical Office
The Federation of State Medical Boards 2013 Model Guidelines for Opioid Addiction Treatment in the Medical Office Adopted April 2013 for Consideration by State Medical Boards 2002 FSMB Model Guidelines
More informationThe patient s response to therapy within the first hour in the Emergency Room is one of the most reliable ways to predict need for hospitalization.
Emergency Room Asthma Management Algorithm The Emergency Room Asthma Management Algorithm is to be used for any patient seen in the Emergency Room with the diagnosis of asthma. (The initial history should
More informationSubstance Abuse lifestyle Concern for mother - fetus - and - neonate
OBJECTIVES Learn about types of opioids and associated withdrawal symptoms Learn what medications are available to treat opioid addiction Understand the pros and cons associated with each medication Understand
More informationPhilip Moore DO, Toxicology Fellow, PinnacleHealth Toxicology Center Joanne Konick-McMahan RN MSRN, Staff RN, PinnacleHealth
Philip Moore DO, Toxicology Fellow, PinnacleHealth Toxicology Center Joanne Konick-McMahan RN MSRN, Staff RN, PinnacleHealth I. II. Background A. AWS can occur in anyone who consumes alcohol B. Risk correlates
More informationMedical marijuana for pain and anxiety: A primer for methadone physicians. Meldon Kahan MD CPSO Methadone Prescribers Conference November 6, 2015
Medical marijuana for pain and anxiety: A primer for methadone physicians Meldon Kahan MD CPSO Methadone Prescribers Conference November 6, 2015 Conflict of interest statement No conflict of interest to
More informationSOUTH CENTRAL NEONATAL NETWORK GUIDELINE. South Central (North) Guideline for Neonatal Drug Withdrawal
SOUTH CENTRAL NEONATAL NETWORK GUIDELINE South Central (North) Guideline for Neonatal Drug Withdrawal Approved by & South Central Neonatal Steering Group for South Central North. date Date of Implementation
More informationUpdate on Buprenorphine: Induction and Ongoing Care
Update on Buprenorphine: Induction and Ongoing Care Elizabeth F. Howell, M.D., DFAPA, FASAM Department of Psychiatry, University of Utah School of Medicine North Carolina Addiction Medicine Conference
More informationNeonatal Abstinence Syndrome: Indian Health Service (IHS) Best Practices Guidelines
Neonatal Abstinence Syndrome: Indian Health Service (IHS) Best Practices Guidelines 1. Neonatal Drug Withdrawal Intrauterine exposure to certain drugs and medications can cause clinical symptoms in the
More informationOpioid Agreement for Center for Pain Management S.C.
Opioid Agreement for Center for Pain Management S.C. Patient Name: DOB: I am the patient named above. I have agreed to use pain medication as part of my treatment for chronic pain. I understand that these
More informationTransitioning Chronic Pain Patients Out of the Hospital. Rosemary Quirk, MD, DTMH ACP, November 7, 2014
Transitioning Chronic Pain Patients Out of the Hospital Rosemary Quirk, MD, DTMH ACP, November 7, 2014 Patients rate baseline chronic pain between 4/10-8/10 on clinic surveys This fact should fundamentally
More informationPain, Addiction & Methadone
Pain, Addiction & Methadone A CHALLENGING INTERFACE METHADONE AND SUBOXONE OPIOID SUBSTITUTION CONFERENCE Objectives 2 Explore the interface between concurrent pain and addiction. Appreciate the challenges
More informationClinical Algorithm & Preferred Medications to Treat Pain in Dialysis Patients
Clinical Algorithm & Preferred Medications to Treat Pain in Dialysis Patients Developed by the Mid Atlantic Renal Coalition and the Kidney End of Life Coalition September 2009 This project was supported,
More informationALCOHOL DETOXIFICATION (IN-PATIENTS) PRESCRIBING GUIDELINE
ALCOHOL DETOXIFICATION (IN-PATIENTS) PRESCRIBING GUIDELINE Authors Sponsor Responsible committee Ratified by Consultant Psychiatrist; Pharmacist Team Manager Medical Director Medicines Management Group
More informationMaintenance of abstinence in alcohol dependence
Shared Care Guideline for Prescription and monitoring of Acamprosate Calcium Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist, Alcohol Services Dr Donnelly
More informationINTOXICATED PATIENTS AND DETOXIFICATION
VAMC Detoxification Decision Tree Updated May 2006 INTOXICATED PATIENTS AND DETOXIFICATION Patients often present for evaluation of substance use and possible detoxification. There are certain decisions
More informationNaloxone Hydrochloride Injection PRODUCT INFORMATION
Naloxone Hydrochloride Injection PRODUCT INFORMATION DESCRIPTION Naloxone hydrochloride is 17-allyl-4,5α-epoxy-3,14-dihydroxymorphinan-6-one hydrochloride; C 19 H 21 NO 4.HCl. It is an off-white powder
More information2. The prescribing clinician will register with the designated manufacturer.
Clozapine Management Program Description Magellan of Arizona Pharmacy Program Background: Magellan Health Services of Arizona recognizes the importance of a clozapine program. Clozapine received increased
More informationConceptualizing and Integrating Medication Assistant Treatment into your Court s Armamentarium
Conceptualizing and Integrating Medication Assistant Treatment into your Court s Armamentarium Ted Parran JR. M.D. FACP Carter and Isabel Wang Professor of Medical Education CWRU School of Medicine tvp@case.edu
More informationAwareness of the inappropriate use of GI prophylaxis and its cost. Adverse effects of proton pump inhibitor
Understand the indication for stress ulcer/gi prophylaxis Awareness of the inappropriate use of GI prophylaxis and its cost Adverse effects of proton pump inhibitor A. 65yo w/ HTN and ESRD on HD p/w left
More informationGuidelines for the use of Methadone for Adults with Pain in Palliative Care
Guidelines for the use of Methadone for Adults with Pain in Palliative Care Date Approved by Network Governance October 2012 Date for Review October 2015 Page 1 of 17 1. Scope of the Guideline 1.1 This
More informationLidocaine Infusion for Perioperative Pain Management. Marley Linder, PharmD Matt McEvoy, MD
Lidocaine Infusion for Perioperative Pain Management Marley Linder, PharmD Matt McEvoy, MD Perioperative Surgical Home: PCS Shared Goals Improved Outcomes (pain, PONV, LOS, SSI) Improve Throughput (Clinic
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2011 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationHealthcare Inspection. Quality of Care Concerns Hospice/Palliative Care Program VA Western New York Healthcare System Buffalo, New York
Department of Veterans Affairs Office of Inspector General Office of Healthcare Inspections Report No. 13-04195-180 Healthcare Inspection Quality of Care Concerns Hospice/Palliative Care Program VA Western
More informationOpioid Prescribing for Chronic Pain: Guidelines for Marin County Clinicians
Opioid Prescribing for Chronic Pain: Guidelines for Marin County Clinicians Although prescription pain medications are intended to improve the lives of people with pain, their increased use and misuse
More informationImplementing Prescribing Guidelines in the Emergency Department. April 16, 2013
Implementing Prescribing Guidelines in the Emergency Department April 16, 2013 Housekeeping Note: Today s presentation is being recorded and will be provided within 48 hours. Two ways to ask questions
More informationOpioid Analgesics. Week 19
Opioid Analgesics Week 19 Analgesic Vocabulary Analgesia Narcotic Opiate Opioid Agonist Antagonist Narcotic Analgesics Controlled substances Opioid analgesics derived from poppy Opiates include morphine,
More information